BladderGLP-1OAB

GLP-1s and Bladder Outcomes

Journal of Women's Health

Dated 13-08-2025

Author: Dr. Amanda Olson, DPT, PRPC President & Chief Clinical Officer

Overactive bladder (OAB) can significantly impact quality of life, and weight loss is known to help reduce symptoms. With the increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists—primarily for weight loss—researchers are exploring whether these medications may have additional benefits for bladder health. This pilot study offers early insights into how GLP-1 therapy might influence OAB symptoms, particularly in patients with more frequent baseline symptoms.

What the Research Shows

Purpose: To explore whether GLP-1 receptor agonists (e.g., semaglutide) affect overactive bladder (OAB) symptoms.
Method: Anonymous online survey of adults (18+) who used GLP-1s and experienced OAB symptoms.
Participants: 33 total; 27 female; 96.9% used semaglutide, mostly for weight loss.
Findings:
- 33.3% (11 participants) reported OAB symptom improvement after starting GLP-1 therapy.
- Average weight loss: 12.2% (improvement group) vs. 8.4% (no change) and 10% (worsening); not statistically significant (p = 0.24).
- 50% of those with daily OAB episodes improved.
- 90.91% of participants who improved had daily OAB before treatment.
Interpretation: Weight loss can improve OAB symptoms, but results suggest GLP-1s may offer additional benefit—especially in patients with more severe baseline symptoms.

What This Means for Clinical Care

GLP-1s may be considered for patients with obesity and frequent or severe OAB symptoms.
Individuals with more pronounced baseline symptoms could see greater benefit.
Findings are preliminary and based on self-reported data; caution in interpretation is warranted.

A Multidisciplinary Approach

Collaboration between urology, primary care, and obesity medicine may help optimize care.
Monitor urinary symptoms alongside weight changes in patients using GLP-1 therapy.
Further research with larger, controlled studies is needed to confirm these observations and explore mechanisms.

Sandler, M. D., Williams, A. D., Wein, A., Amin, K., & Syan, R. (2025). Effects of Glucagon like Peptide-1 agonists on patients with overactive bladder: A pilot study. Continence Reports, 100083.

Become and Intimate Rose Partner

Get provider-only pricing, ready-to-share patient resources, and clinical training – whatever your specialty.

Apply Now

Related Reports Back to Library

About Dr. Amanda Olson, DPT, PRPC

Dr. Amanda Olson brings both clinical expertise and lived experience to pelvic health. Following a significant coccyx and pelvic floor injury, her recovery through comprehensive pelvic physical therapy shaped her clinical approach. She subsequently transitioned from pediatrics to specialize in pelvic health. Her work now informs the development and education behind Intimate Rose.